|  |
|  |
|  | | PerkinElmer Expands Global R&D Base in Singapore |  |  | | PerkinElmer Inc., a global technology leader in Health Sciences and Photonics, opened a new Centre of Excellence in Singapore. The PerkinElmer Inc. Centre of Excellence in Singapore will serve as a base for the Company's R&D efforts in Asia, and will focus on the development of new precision instrumentation and chemistries for a range of scientific and industrial laboratory applications, including drug discovery and development, environmental monitoring, food safety, and sustainable energy. |
| | | | | GlaxoSmithKline Opens New Research & Development Pilot Plant | | | | GSK celebrated the completion of its new Research & Development (R&D) Pilot Plant facility in Singapore with an opening ceremony, graced by Mr S Iswaran, Minister of State for Trade & Industry and Dr Moncef Slaoui, Chairman, R&D, GSK. This $116 million facility was built to accommodate the final phase of development of potential new medicines. The pilot plant will create synergistic opportunities and enhance GSK's capability to streamline and accelerate the delivery of innovative medicines to patients. |
| | | | | Millipore Corporation Announces New Facility in Singapore | | | | Millipore Corporation will be opening a new applications and training facility in Singapore, to meet the growing needs of its biotech customers in Asia. Located in the Science Park, this facility is scheduled to open in early 2009. It will support biopharmaceutical manufacturing, as well as allow local and regional customers to investigate, explore and optimize their separations, purifications and monitoring processes. |
| | | | | bioMérieux Opens Singapore Subsidiary | | | | bioMérieux opened a subsidiary and regional office in Singapore, which will provide support to all of its Asia Pacific commercial operations. Based in the Biopolis, this subsidiary will provide the company with direct access to their Asian clients and the proximity to establish collaborations with Singapore's vibrant biomedical industry. bioMérieux is a world leader in the field of in vitro diagnostics and this is the company's 38th subsidiary. |
| | | | | Alexza Completes US$10 Million Equity Financing with Bio*One Capital to Initiate Commercial Manufacturing in Singapore | | | | Alexza Pharmaceuticals, Inc. announced that it intends to initiate manufacturing operations for key components of Alexza's single-dose Staccato device in Singapore. Alexza's single-dose Staccato devices are used in a majority of its current product candidates, including its lead program, AZ-004 (Staccato loxapine), which is in Phase 3 clinical testing for the treatment of acute agitation in schizophrenic or bipolar disorder patients. Alexza's technology and Staccato device offer patients a new paradigm to rapid systemic drug delivery through deep lung inhalation. |
| | | | | Singapore establishes Cancer Research Centre of Excellence | | | Singapore's National Research Foundation and Ministry of Education have committed S$172 million to set up the Cancer Research Centre of Excellence at the National University of Singapore (NUS). The Cancer RCE will be led by Professor Daniel Tenen who has joined NUS from Harvard Medical School. Professor Tenen is a leader in the field of transcriptional regulation, hematopoiesis and cancer. Other prominent scientists who will be joining the RCE include Professor Yoichi Taya from Japan's National Cancer Center Research Institute and Professor Fu Xin Yuan, formerly from Yale University and Indiana University, to name a few. These new faculty will be working alongside lead researchers at the Institute of Molecular and Cell Biology, A*STAR, National University Hospital, Duke-NUS Graduate Medical School, the John Hopkins Singapore International Medical Centre and the Ludwig Institute of Cancer Research.
This Cancer Research Centre of Excellence will strengthen Singapore's prominent role in providing solutions to Asia's cancer predicament; especially when more than half of the world's cancer burden will reside in Asia in the near future.
|
| | | | | Duke-NUS launches Asia's first Palliative Care Research Centre | | | | Duke-NUS Medical School and the Lien Foundation have established The Lien Centre for Palliative Care. This research centre will draw on the capabilities of Duke-NUS, with support from the National Cancer Centre Singapore and Singapore Health Services. The centre will be led by Dr Cynthia Goh, a veteran palliative care pioneer and medical specialist. This facility will enhance Singapore's expertise in palliative care and research. The Lien Foundation has committed $7.5 million to the centre over five years, which will be matched by the Singapore government. |
| | | | | Singapore firm Veredus set up joint lab with STMicroelectronics | | | Veredus Laboratories and STMicroelectronics announced the commercial viability of VereFlu, a portable lab-on-chip application for rapid detection of all major influenza types at the point of need, following successful evaluation trials at NUS. VereFlu is a breakthrough molecular diagnostic test that can detect infection with high accuracy and sensitivity, within two hours providing genetic information of the infection that traditionally would take days to weeks to learn. With its high level of automation, users outside the traditional lab environment can easily perform the tests at the point of need.
Following the successful commercial launch of the Vereflu project, STMicroelectronics and Veredus Laboratories have set up a joint lab, the Bio-Application Lab, where experts from both companies will work together on the development of new biomedical applications based on ST's In-Check lab-on-chip platform. Future application areas of interest include other infectious diseases, oncology and heart-disease markers.
|
| | | | | | |
留言列表
留言列表
